Department of Emergency Medicine, University of California, San Francisco, 521 Parnassus Avenue, 7th Floor, Box 0203, San Francisco, CA, 94143, USA.
Center for Public Health Research, San Francisco Department of Public Health, 25 Van Ness Avenue, San Francisco, CA, 94102, USA.
Addict Sci Clin Pract. 2024 Nov 20;19(1):84. doi: 10.1186/s13722-024-00515-0.
Rates of cocaine use disorder (CUD) among men who have sex with men (MSM) are high and rising. Among MSM, cocaine use is associated with negative socioeconomic, medical, and psychological outcomes. There are no FDA-approved pharmacotherapy options to treat CUD, and psychosocial interventions demonstrate limited efficacy. While there have been numerous trials evaluating possible medications for CUD, there is a scarcity of qualitative data on the barriers and facilitators of medication-assisted treatment.
Semi-structured interviews were conducted with 16 participants enrolled in a phase II randomized control trial evaluating extended-release lorcaserin among MSM with CUD. Participants were asked about their motivations for enrolling in the study, attitudes towards taking a medication for CUD, barriers and facilitators of study pill adherence, and their general study experience. Interviews were analyzed using an inductive and exploratory approach to thematic analysis.
Participants were highly motivated to reduce cocaine use and viewed pharmacotherapy as a viable and desirable treatment option. Pharmacotherapy was seen as having fewer access and adherence structural barriers compared to existing psychosocial therapies. Medication reminders facilitated pill taking, while side effects, travel, and active substance use presented barriers to study pill adherence. Disclosure of study participation within social networks was variable pointing to anticipated substance use and treatment stigma.
Our study highlights important factors affecting the acceptability and uptake of medication-assisted treatment for CUD among a diverse sample of MSM. These findings can help guide the development and implementation of future pharmacotherapy options for CUD and other substance use disorders in this key population.
男男性行为者(MSM)中可卡因使用障碍(CUD)的发生率很高且呈上升趋势。在 MSM 中,可卡因使用与负面的社会经济、医疗和心理后果相关。目前没有 FDA 批准的治疗 CUD 的药物疗法选择,而心理社会干预的疗效有限。虽然已经有许多试验评估了治疗 CUD 的可能药物,但关于药物辅助治疗的障碍和促进因素的定性数据却很少。
对 16 名参加评估 CUD 中延长释放型氯卡色林的 II 期随机对照试验的参与者进行了半结构式访谈。参与者被问及他们参加研究的动机、对治疗 CUD 的药物的态度、研究药物依从性的障碍和促进因素,以及他们的一般研究经验。使用归纳和探索性方法对访谈进行主题分析。
参与者非常有动力减少可卡因使用,并将药物治疗视为可行且理想的治疗选择。与现有的心理社会疗法相比,药物治疗被认为具有较少的获得和依从结构障碍。药物提醒有助于服药,而副作用、旅行和主动物质使用则成为研究药物依从性的障碍。在社交网络中披露研究参与情况存在差异,这表明存在预期的物质使用和治疗污名。
我们的研究强调了影响 MSM 中 CUD 药物辅助治疗的可接受性和采用的重要因素。这些发现可以帮助指导未来 CUD 和其他物质使用障碍在这一关键人群中药物治疗选择的开发和实施。